福森药业(01652.HK)“恩扎卢胺软胶囊”上市许可申请获受理

阿斯达克财经05-31

福森药业(01652.HK) 公布，全资附属嘉亨(珠海横琴)研发“恩扎卢胺软胶囊”的上市申请已获中国国家药品监督管理局受理。恩扎卢胺软胶囊用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌成年患者；及雄激素剥夺治疗失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌成年患者的治疗。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2439627758?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200428104427393_s.jpg","is_english":false,"pubTime":"2024-05-31 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2439627758","market":"other","top_or_hot":-1,"title":"福森药业(01652.HK)“恩扎卢胺软胶囊”上市许可申请获受理","media":"阿斯达克财经","content":"<div>\n<p>福森药业(01652.HK) 公布，全资附属嘉亨(珠海横琴)研发“恩扎卢胺软胶囊”的上市申请已获中国国家药品监督管理局受理。恩扎卢胺软胶囊用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌成年患者；及雄激素剥夺治疗失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌成年患者的治疗。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1353304/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>福森药业(01652.HK)“恩扎卢胺软胶囊”上市许可申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n福森药业(01652.HK)“恩扎卢胺软胶囊”上市许可申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-31 00:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1353304/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>福森药业(01652.HK) 公布，全资附属嘉亨(珠海横琴)研发“恩扎卢胺软胶囊”的上市申请已获中国国家药品监督管理局受理。恩扎卢胺软胶囊用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌成年患者；及雄激素剥夺治疗失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌成年患者的治疗。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1353304/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1353304/latest-news/AAFN","article_id":"2439627758","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200428104427393_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2439627758","pubTimestamp":1717087680,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"福森药业(01652.HK) 公布，全资附属嘉亨(珠海横琴)研发“恩扎卢胺软胶囊”的上市申请已获中国国家药品监督管理局受理。恩扎卢胺软胶囊用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌成年患者；及雄激素剥夺治疗失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌成年患者的治疗。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","01652":"福森药业"},"translate_title":"Fusen Pharmaceutical (01652. HK) Marketing Authorization Application for \"Enzalutamide Soft Capsules\" Accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"福森药业(01652.HK) 公布，全资附属嘉亨(珠海横琴)研发“恩扎卢胺软胶囊”的上市申请已获中国国家药品监督管理局受理。恩扎卢胺软胶囊用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌成年患者；及雄激素剥夺治疗失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌成年患者的治疗。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2439627758"}